Curriculum Vitae [ CV ]
A double board-certified internist and medical oncologist, Jeffrey Turner, MD, has been specializing full time in the treatment of prostate cancer since 2009. He joined Prostate Oncology Specialists, Inc., Marina del Rey in December 2012.
Dr. Turner is an active member of the American Society of Clinical Oncology, American Society of Hematology and American College of Physicians-Internal Medicine. He has written various publications on urologic cancers with an emphasis on prostate cancer and is a sub-investigator of a number of ongoing prostate cancer clinical trials. In addition to his physician duties, he is a guest speaker at various prostate cancer support groups.
Dr. Turner graduated cum laude and was the first student to graduate with a bachelor’s degree in biological sciences at USC’s three year accelerated science program. Thereafter, he was a research associate at UCLA in infectious diseases and molecular biology. He then earned his medical degree in Canada at Memorial University of Newfoundland. He completed his internal medicine residency at the University of British Columbia and fellowship in medical oncology at the Medical University of South Carolina.
He currently resides in Long Beach, CA.
Medical Board of California – Physicians and Surgeons License 2006. A94409
American Board of Medical Oncology 2009
American Board of Internal Medicine 2006
Fellowship Medical University of South Carolina, Charleston, SC – Medical Oncology, 2007-2009
Residency University of British Columbia, Vancouver, BC – Internal Medicine, 2003-2006
Medical School Memorial University of Newfoundland – 1999-2003
University University of Southern California (USC) – Biological Sciences, B.A., 1993-1996
Honors and Awards
Super Doctors, Southern California Rising Stars 2015
Super Doctors, Southern California Rising Stars 2014
Super Doctors, Southern California Rising Stars 2013
UBC Annual Resident Research Day – Best Poster 2005: Comparison of Combined Chemotherapy to Conventional Radiotherapy in the Treatment of Stage 2A/B Testicular Seminoma.
Graduated cum laude, 1996
First student to graduate from three-year accelerated science program 1996
Dean’s Scholar / Golden State Scholar / ‘SCions Scholar / Golden Key Nat’l Honor Society 1996
American Society of Clinical Oncology
American Society of Hematology
American College of Physicians
Scholz, Mark C., S. Yep, C. Kelly, Khang N. Chau, Jeffrey S. Turner, and Richard Y. Lam. Phase I trial of sipuleucel-T combined with ipilimumab (SIPIPI) in progressive M-CRPC. Abstract. Journal of Clinical Oncology 34 (2016).
Almeida, Fabio, Steven Finkelstein, Larry Bans, Mark Scholz, Richard Lam, and Jeffrey Turner. Performance Characteristics and Influence of PSA Value/Kinetics on Carbon-11 Acetate PET/CT
Imaging in Biochemical Relapse of Prostate Cancer. Presentation at the International Prostate Cancer Update 2016.
Scholz, Mark C., Richard Y. Lam, Jeffrey S. Turner, and Clifford U. Felarca. Y-90 Resin Castrate-Resistant Prostate Cancer with Liver Metastasis. Poster at the Gastrointestinal Cancer Symposium 2016.
Scholz, Mark Creamer, Richard Y. Lam, Jeffrey S. Turner, Khang N. Chau, Lauren K. Becker, and Clifford U. Felarca. “Enzalutamide in men with prostate cancer resistant to docetaxel and abiraterone.” In ASCO Annual Meeting Proceedings, vol. 32, no. 4_suppl, p. 247. 2014.
Drabkin, Harry A., and Jeffrey Turner. “Renal Cancer Pathogenesis.” In Encyclopedia of Cancer, pp. 3238-3241. Springer Berlin Heidelberg, 2011.
Chaudhary, Uzair B., and Jeffrey S. Turner. “Finasteride.” Expert opinion on drug metabolism & toxicology 6, no. 7 (2010): 873-881.
Turner, J. S., C. S. Chen, W. Butler, J. Bearden III, E. Garrett-Mayer, G. Onicescu, and A. S. Kraft. “Bortezomib therapy for prostate specific antigen (PSA)-only relapse after definitive local therapy.” Abstract. Journal of Clinical Oncology 27 (2009).
Turner, Jeffrey, and Uzair Chaudhary. “Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate cancer.” Anti-cancer drugs 20, no. 3 (December 2009): 215-216.
Verma, Nitin, John Lazarchick, Vinay Gudena, Jeffrey Turner, and Uzair B. Chaudhary. “Testicular lymphoma: an update for clinicians.” The American journal of the medical sciences 336, no. 4 (October 2008): 336-341.
Turner, Jeffrey S., Eric M. Cheung, Jaya George, and David I. Quinn. “Pain management, supportive and palliative care in patients with renal cell carcinoma.” BJU international 99, no. 5b (April 2007): 1305-1312.
Yasin, B., M. Pang, J. S. Turner, Y. Cho, N. N. Dinh, A. J. Waring, R. I. Lehrer, and E. A. Wagar. “Evaluation of the inactivation of infectious herpes simplex virus by host-defense peptides.” European Journal of Clinical Microbiology and Infectious Diseases 19, no. 3 (March 2000): 187-194.
Lee, S., F. Espin, J. Turner, M. Griswold, and D. Kahn. “Genotyping of HIV-1 drug-resistance: comparison between in-house procedure and visible genetics Trugene [Tm] HIV-1 assay.” Abstract. Abstracts of Conference on Antimicrobial Agents and Chemotherapy 39 (September 1999): 462.
Cho, Yoon, Jeffrey S. Turner, Nhu-Nguyen Dinh, and Robert I. Lehrer. “Activity of Protegrins against Yeast-Phase Candida albicans.” Infection and immunity 66, no. 6 (June 1998): 2486-2493.
Turner, Jeffrey, Yoon Cho, Nhu-Nguyen Dinh, Alan J. Waring, and Robert I. Lehrer. “Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils.” Antimicrobial agents and chemotherapy 42, no. 9 (September 1998): 2206-2214.
ARMOR3-SV, Phase 3: Trial of Galeterone in Men with Metastatic Castrate Resistant Prostate Cancer who’s Tumors Express the AR-V7 Splice Variant.
GU12-159 PACIFIC: OGX-427 in Metastatic Castrate-Resistant Prostate Cancer with Prostate-Specific Antigen Progression While Receiving Abiraterone.
OGX-011-12 AFFINITY: Comparison of Cabazitaxel/Prednisone Alone or in Combination with Custirsen for 2nd Line Chemotherapy in Prostate Cancer (AFFINITY).
ONC-MA-1004 TRUMPET: Observational Cohort Study of Patients with Castrate-Resistant Prostate Cancer on Lupron starting Enzalutamide/Abiraterone.
P10-3 PROCEED: A Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer (PROCEED).
P11-4 PRIME: Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T (PRIME).
P11-4 PRIME, Phase 4: Immune Monitoring Protocol in Men with Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T.
P12-1 PREDICT: Observational Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Metastatic Disease in Castrate-Resistant Prostate Cancer.
SIPIPI 2013: Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer.
SP005 VIABLE, Phase 3: DVAC Added to Standard Chemotherapy for Men With Metastatic Castrate Resistant Prostate Cancer.
XL184-306 COMET-2: Study of Cabozantinib (XL184) Versus Mitoxantrone plus Prednisone in Men with Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2).